Liquidyne Process Technologies, Inc

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) & TP53 mutant AML Patients

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) & TP53 mutant AML Patients Shattuck Labs, Inc. announced updated interim data from the Phase 1B dose expansion clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients.

Looking for best-in-class 𝐂𝐮𝐬𝐭𝐨𝐦 𝐏𝐮𝐦𝐩 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 for your process? From simple to complex, can help solve your most pressing process challenges. Learn more! https://liquidyneusa.com/pages/custom-pump-solutions-bipharma

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201 Cabaletta Bio, Inc. reported positive initial clinical data from each of the first two patients dosed with CABA-201 in the Phase 1/2 RESET-Myositis and RESET-SLE trials.

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress Editas Medicine, Inc., a clinical-stage genome editing company, announced new safety and efficacy data in 18 patients living with sickle cell disease treated with renizgamglogene autogedtemcel in the Phase 1/2/3 RUBY clinical trial.

Rigel Announces Five Presentations at the EHA2024 Hybrid Congress

Rigel Announces Five Presentations at the EHA2024 Hybrid Congress Rigel Pharmaceuticals, Inc. announced one oral and four poster presentations at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain being held June 13-16, 2024, and online.

Introducing the custom Quattroflow 1200 OEM Pump – tailored precision for your needs! 🛠️ Dive into seamless integration, enhanced performance, and the trusted Quattroflow quality, all wrapped in a custom-built package. 'Fluid transfer your way' - why settle for standard when you can go custom? 🌟 https://liquidyneusa.com/pages/landing-custom-sanitary-pumps-for-biopharma-manufacturing

Getting it wrong is too costly. Find out what Single-Use pump is best for your new/existing biologics process.
https://liquidyneusa.com/what-single-use-pump-is-best-for-biologics-production/

Honoring Impact: Trish Melton, PhD, Recognized with the 2025 ISPE Richard B. Purdy Distinguished Achievement Award

Honoring Impact: Trish Melton, PhD, Recognized with the 2025 ISPE Richard B. Purdy Distinguished Achievement Award The 2025 ISPE International Honor Awards took place during the Membership Meeting and Awards Lunch at the 2025 ISPE Annual Meeting & Expo hosted in Charlotte, North Carolina, USA from 26-29 October. The ceremony honored ISPE members and contributors whose dedication and service exemplify what it mea...

How Generative AI is Transforming Deviation Management: Lessons from Integrating Microsoft Copilot in Pharma Quality Systems

How Generative AI is Transforming Deviation Management: Lessons from Integrating Microsoft Copilot in Pharma Quality Systems Introduction: The Human Challenge Behind Deviation ManagementA deviation is more than a record of non-conformance; it is a narrative of how an organization understands its processes and strengthens them. In pharmaceutical manufacturing, deviation management forms the foundation of product quality, r...